

ISO 20916:2019 (E)

In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects — Good study practice

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	Ethical considerations
4.1	General
4.2	Improper influence or inducement
4.3	Responsibilities
4.4	Ethics committee involvement
4.5	Informed consent
5	Clinical performance study planning
5.1	General
5.2	Risk evaluation
5.3	Design of the clinical performance study
5.4	Investigator brochure
5.5	Clinical Performance Study Protocol (CPSP)
5.5.1	General
5.5.2	Principal investigator responsibilities
5.5.3	Contents of the CPSP
5.5.3.1	General
5.5.3.2	Identification of the clinical performance study protocol
5.5.3.3	Identification and description of the IVD medical device under investigation
5.5.3.4	Sponsor
5.5.3.5	Study site(s)
5.5.3.6	Overall synopsis of the clinical performance study
5.5.3.7	Objectives of the clinical performance study
5.5.3.8	IVD medical device under investigation and comparator(s)
5.5.3.9	Specimens and when applicable, subjects providing specimens
5.5.3.10	Procedures
5.5.3.11	Monitoring plan
5.5.3.12	Data management
5.5.3.13	Statistical considerations
5.5.3.14	Amendments to the CPSP
5.5.3.15	Deviations from clinical performance study protocol
5.5.3.16	Accountability of IVD medical devices under investigation
5.5.3.17	Statements of conformity
5.5.3.18	Informed consent process
5.5.3.19	Adverse events, adverse device effects and device deficiencies
5.5.3.20	Bibliography
5.6	Case report forms
5.7	Recording of specimen information
5.8	Specimen accountability and integrity
5.9	Study site selection
5.9.1	Site qualification
5.9.2	Site assessment
5.9.3	Site selection

5.10	Monitoring plan
5.11	Agreements
5.12	Labelling
6	Study site initiation
6.1	General
6.2	Prerequisites
6.3	Training
6.4	Initiation of the study site
7	Clinical performance study conduct
7.1	General
7.2	Responsibilities of the sponsor
7.3	Study site monitoring
7.3.1	General
7.3.2	Routine monitoring
7.3.3	Monitoring reports
7.4	Security and confidentiality of data
8	Close-out of the clinical performance study
8.1	Close-out activities
8.2	Clinical performance study report
8.3	Document retention
8.4	Suspension or premature termination of the clinical performance study
9	Auditing
Annex A (normative) Additional general requirements for certain studies	
A.1	Introduction
A.2	Ethics committee approval
A.3	Informed consent
A.4	Accounting for subjects
A.5	Case report forms
A.6	Suspension or termination of a clinical performance study
A.6.1	Procedure for suspension/termination
A.6.2	Procedure for resuming the clinical performance study after temporary suspension
A.7	Medical care of subjects
A.8	Compensation
A.9	Vulnerable populations
Annex B (normative) Clinical performance study protocol (CPSP)	
B.1	General
B.2	Identification and description of the IVD medical device under investigation
B.3	Identification of the clinical performance study protocol
B.4	Sponsor
B.5	Principal investigator and study site(s)
B.6	Overall synopsis of the clinical performance study
B.7	Risks and benefits of the IVD medical device under investigation and clinical performance study
B.8	Design of the clinical performance study
B.8.1	General
B.8.2	IVD medical device under investigation and comparator(s)
B.8.3	Specimens and when applicable, subjects providing specimens
B.8.4	Procedures
B.8.5	Monitoring plan
B.8.6	Data management
B.8.7	Statistical considerations
B.8.8	Deviations from clinical performance study protocol
B.8.9	Accountability of IVD medical devices under investigation
B.8.10	Insurance
B.8.11	Adverse events, adverse device effects and device deficiencies
B.8.12	Vulnerable population
B.8.13	Suspension or premature termination of the clinical performance study
B.8.14	Publication and Communication policy

B.8.15 Bibliography

Annex C (normative) Investigator brochure

- C.1 Introduction**
- C.1.1 General**
- C.1.2 Identification of the investigator brochure**
- C.1.3 Sponsor**
- C.2 Information on IVD medical device under investigation**
- C.3 Analytical testing**
- C.4 Existing clinical performance data**
- C.5 Risk management**
- C.6 Regulatory and other references**

Annex D (normative) Clinical performance study report

- D.1 General**
- D.2 Signature page**
- D.3 Cover page**
- D.4 Table of contents**
- D.5 Summary**
- D.6 Introduction**
- D.7 IVD medical device under investigation and methods**
- D.7.1 Description of the IVD medical device under investigation**
- D.7.2 Clinical performance study protocol (CPSP)**
- D.8 Results**
- D.9 Discussion and overall conclusions**
- D.10 Abbreviated terms and definitions**
- D.11 Ethics**
- D.12 Investigators and administrative structure of clinical performance study**
- D.13 Annexes to the report**

Annex E (normative) Communication with the ethics committee

- E.1 Introduction**
- E.2 Initial ethics committee submission**
- E.3 Information to be obtained from the ethics committee**
- E.4 Continuing communication with the ethics committee**
- E.5 Continuing information to be obtained from the ethics committee**

Annex F (normative) Informed consent

- F.1 General**
- F.2 Process of obtaining informed consent**
- F.3 Special circumstances for informed consent**
- F.3.1 General**
- F.3.2 Subject needing legally authorized representatives**
- F.3.3 Subject unable to read or write**
- F.4 Information to be provided to the subject**
- F.5 Informed consent signature**
- F.6 New information**

Annex G (normative) Adverse event categorization

- G.1 Direct and indirect harms**
- G.2 Categories of adverse events**
- G.3 Safety evaluation and monitoring**
- G.4 Safety recording and reporting**

Annex H (informative) Good clinical performance study documentation

Annex I (informative) Auditing